Blocking STAT3 reactivation by combining dasatinib with Janus kinase (JAK) inhibition resulted in synergistic cytotoxicity in different tumor cells [121]; however this strategy has not yet been tested on MM cells. This evidence concerns the gene STAT3 and Miyoshi myopathy.